nference Enters into an R&D Data Science Strategic Partnership with Janssen
Summary
By pairing the unique data science technologies enabled by the nference platform with the renowned institutional expertise of Janssen R&D, we seek to unearth answers to complex research questions and solve urgent business needs. This is enabled via an agile data science-enabled business platform and a living software kernel that continually synthesize public as well as proprietary knowledge across therapeutic areas and global support functions,” said Venky Soundararajan, Ph.D., Founder and Chief Scientific Officer of nference. George Church, Ph.D., who joins as Chairman of the nference Scientific Advisory Board, added, “ This alliance heralds the coming together of breakthrough machine intelligence, profound biomedical insights and iterative software application development to power drug discovery, disease stratification and clinical development for one of the largest pharmaceutical companies.” Dr. Church, Professor at Harvard Medical School and Massachusetts Institute of Technology, is widely recognized as a founding father of human genome sequencing (including next-generation sequencing, nanopores) and for genome editing (CRISPR), writing, recoding and the world’s only open-access personal precision medicine databases. The concomitant pursuit of diverse research collaborations and the advancement of a comprehensive software-as-a-service (SaaS) platform are expected to produce meaningful synergies that are truly distinctive in the pharmaceutical industry. nference is making biomedical knowledge computable, and building its AI platform to serve as the connective fabric for various silos of information that exist in unstructured and structured form across health care enterprises.